Similar articles

Abstract: Objective: To evaluate the comparative therapeutic efficacy of radiofrequency ablation (RFA) and hepatic resection (HR) for breast cancer liver metastases (BCLMs). Methods: Studies that had examined the outcomes for both RFA and HR for BCLM were identified by searching the electronic databases PubMed, EMBASE, and the Cochrane Library. Pooled analyzes of the overall survival (OS), disease-free survival (DFS), and short-term outcomes of BCLM were performed. Results: Patients with BCLM gained many more survival benefits from HR than from RFA with regard to the 3-year OS rate (combined odds ratio (OR) 0.41, 95% confidence interval (CI) 0.29–0.59, P<0.001), 5-year OS rate (combined OR 0.38, 95% CI 0.32–0.46, P<0.001), 3-year DFS (combined OR 0.36, 95% CI 0.27–0.49, P<0.001), and 5-year DFS (combined OR 0.51, 95% CI 0.40–0.66, P<0.001). RFA had fewer postoperative complications (combined OR 0.30, 95% CI 0.20–0.44, P<0.001) and shorter hospital stays (combined OR −9.01, 95% CI −13.49–4.54, P<0.001) than HR. Conclusions: HR takes precedence over RFA in the treatment of patients with BCLM, considering the better survival rate. RFA gives rise to fewer complications and can be carried out with a shorter hospital stay, compared to HR. RFA should be reserved for patients who are not optimum candidates for resection.


Retraction of this paper was initiated at the authors' request, as they need to check the original data and analysis for the mistakes pointed out by independent researchers after the publication.

射频消融术与肝切除术治疗乳腺癌肝转移:系统回顾和meta分析

[1]Abraham NS, Byrne CJ, Young JM, et al., 2010. Meta-analysis of well-designed nonrandomized comparative studies of surgical procedures is as good as randomized controlled trials. J Clin Epidemiol, 63(3):238-245.

[2]Adam R, Aloia T, Krissat J, et al., 2006. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg, 244(6):897-908.

[3]Barral M, Auperin A, Hakime A, et al., 2016. Percutaneous thermal ablation of breast cancer metastases in oligometastatic patients. Cardiovasc Intervent Radiol, 39(6):885-893.

[4]Bortolotto C, Macchi S, Veronese L, et al., 2012. Radiofrequency ablation of metastatic lesions from breast cancer. J Ultrasound, 15(3):199-205.

[5]Bruners P, Schmitz-Rode T, Günther RW, et al., 2008. Multipolar hepatic radiofrequency ablation using up to six applicators: preliminary results. Rofo, 180(3):216-222.

[6]Carrafiello G, Fontana F, Cotta E, et al., 2011. Ultrasound-guided thermal radiofrequency ablation (RFA) as an adjunct to systemic chemotherapy for breast cancer liver metastases. Radiol Med, 116(7):1059-1066.

[7]Corona SP, Sobhani N, Ianza A, et al., 2017. Advances in systemic therapy for metastatic breast cancer: future perspectives. Med Oncol, 34(7):119.

[8]Covey AM, Sofocleous CT, 2008. Radiofrequency ablation as a treatment strategy for liver metastases from breast cancer. Semin Intervent Radiol, 25(4):406-412.

[9]Detry O, Warzee F, Polus M, et al., 2003. Liver resection for noncolorectal, nonneuroendocrine metastases. Acta Chir Belg, 103(5):458-462.

[10]Frezza EE, Wachtel MS, Barragan B, et al., 2007. The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendosc Adv Surg Tech A, 17(3):282-284.

[11]Gillams AR, 2005. The use of radiofrequency in cancer. Br J Cancer, 92(10):1825-1829.

[12]Golse N, Adam R, 2017. Liver metastases from breast cancer: what role for surgery? Indications and results. Clin Breast Cancer, 17(4):256-265.

[13]Gunabushanam G, Sharma S, Thulkar S, et al., 2007. Radiofrequency ablation of liver metastases from breast cancer: results in 14 patients. J Vasc Interv Radiol, 18(1):67-72.

[14]Illing R, Gillams A, 2010. Radiofrequency ablation in the treatment of breast cancer liver metastases. Clin Oncol (R Coll Radilo), 22(9):781-784.

[15]Keil S, Bruners P, Ohnsorge L, et al., 2010. Semiautomated versus manual evaluation of liver metastases treated by radiofrequency ablation. J Vasc Interv Radiol, 21(2):245-251.

[16]Kim ES, Scott LJ, 2017. Palbociclib: a review in HR-positive, HER2-negative, advanced or metastatic breast cancer. Target Oncol, 12(3):373-383.

[17]Kümler I, Parner VK, Tuxen MK, et al., 2015. Clinical outcome of percutaneous RFA-ablation of non-operable patients with liver metastasis from breast cancer. Radiol Med, 120(6):536-541.

[18]Lai C, Jin RA, Liang X, et al., 2016. Comparison of laparoscopic hepatectomy, percutaneous radiofrequency ablation and open hepatectomy in the treatment of small hepatocellular carcinoma. J Zhejiang Univ-Sci B (Biomed & Biotechnol), 17(3):236-246.

[19]Lee HY, Ko HK, Kim SH, et al., 2013. Percutaneous radiofrequency ablation for liver metastases in breast cancer patients. Breast J, 19(5):563-565.

[20]Livraghi T, Goldberg SN, Solbiati L, et al., 2001. Percutaneous radio-frequency ablation of liver metastases from breast cancer: initial experience in 24 patients. Radiology, 220(1):145-149.

[21]Mansour M, Teo ZL, Luen SJ, et al., 2017. Advancing immunotherapy in metastatic breast cancer. Curr Treat Options Oncol, 18(6):35.

[22]Meattini I, Desideri I, Francolini G, et al., 2017. Systemic therapies and cognitive impairment for breast cancer: an overview of the current literature. Med Oncol, 34(5):74.

[23]Meloni MF, Andreano A, Laeseke PF, et al., 2009. Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation-intermediate and long-term survival rates. Radiology, 253(3):861-869.

[24]Moher D, Liberati A, Tetzlaff J, et al., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med, 21:6(7):e1000097.

[25]Nordmann AJ, Kasenda B, Briel M, 2012. Meta-analyses: what they can and cannot do. Swiss Med Wkly, 142: w13518.

[26]Parmar MK, Torri V, Stewart L, 1998. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med, 17(24):2815-2834.

[27]Ruiterkamp J, Ernst MF, 2011. The role of surgery in metastatic breast cancer. Eur J Cancer, 47(S3):S6-S22.

[28]Samaan NA, Buzdar AU, Aldinger KA, et al., 1981. Estrogen receptor: a prognostic factor in breast cancer. Cancer, 47(3):554-560.

[29]Sato T, Sato S, Kato K, et al., 2006. Two cases of radiofrequency ablation (RFA) therapy for control of liver metastases from breast cancer. Jpn J Cancer Chemother, 33(12):1904-1906 (in Japanese).

[30]Selzner M, Morse MA, Vredenburgh JJ, et al., 2000. Liver metastases from breast cancer: long-term survival after curative resection. Surgery, 127(4):383-389.

[31]Sofocleous CT, Nascimento RG, Gonen M, et al., 2007. Radiofrequency ablation in the management of liver metastases from breast cancer. Am J Roentgenol, 189(4):883-889.

[32]Stang A, 2010. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 25(9):603-605.

[33]Travaini LL, Trifirò G, Ravasi L, et al., 2008. Role of [¹⁸F]FDG-PET/CT after radiofrequency ablation of liver metastases: preliminary results. Eur J Nucl Med Mol Imaging, 35(7):1316-1322.

[34]Treska V, Liska V, Skalicky T, et al., 2012. Non-colorectal liver metastases: surgical treatment options. Hepatogastroenterology, 59(113):245-248.

[35]Treska V, Cerna M, Liska V, et al., 2014. Surgery for breast cancer liver metastases-factors determining results. Anticancer Res, 34(3):1281-1286.

[36]Veltri A, Gazzera C, Barrera M, et al., 2014. Radiofrequency thermal ablation (RFA) of hepatic metastases (METS) from breast cancer (BC):an adjunctive tool in the multimodal treatment of advanced disease. Radiol Med, 119(5):327-333.

[37]Vogl TJ, Emam A, Naguib NN, et al., 2015. How effective are percutaneous liver-directed therapies in patients with non-colorectal liver metastases? Viszeralmedizin, 31(6):406-413.

[38]Wong J, Cooper A, 2016. Local ablation for solid tumor liver metastases: techniques and treatment efficacy. Cancer Control, 23(1):30-35.

[39]Yun BL, Lee JM, Baek JH, et al., 2011. Radiofrequency ablation for treating liver metastases from a non-colorectal origin. Korean J Radiol, 12(5):579-587.

[40]Zhang J, Liu Y, 2008. HER2 over-expression and response to different chemotherapy regimens in breast cancer. J Zhejiang Univ Sci B, 9(1):5-9.